Is Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) A Better Buy Than Others After A -32.56% Fall In This Year?
In last trading session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) saw 0.62 million shares changing hands with its beta currently measuring 2.42. Company’s recent per share